94.1 percent of Kuwaiti Women Consider Thalassemia Screening after Learning about Health Risks

BGI Genomics Bahrain Iran Iraq Jordan Kuwait Lebanon Oman Palestine Qatar Saudi Arabia Syria United Arab Emirates Yemen China

to access the BGI Genomics State of State of Thalassemia Awareness Report 2023.

About BGI Genomics and thalassemia screening tests

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

The company has pioneered thalassemia genetic testing services based on next-generation sequencing (NGS) technology since 2013. Expanding the availability of genetic testing has been instrumental in the screening, diagnosing, and treating thalassemia.

Photo - https://mma.prnewswire.com/media/2277826/BGI.jpg
Logo - https://mma.prnewswire.com/media/1608027/BGI_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/94-1-percent-of-kuwaiti-women-consider-thalassemia-screening-after-learning-about-health-risks-301989414.html